Tango Therapeutics
TNGX
38 hedge funds and large institutions have $137M invested in Tango Therapeutics in 2020 Q3 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
63.33% more ownership
Funds ownership: 0% → 63.33% (+63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.8M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
+$8.68M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$8.17M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$8.17M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.17M |
Top Sellers
TNGX Hedge Fund Activity: Q3 2020 in Review
38 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q3 2020, worth a combined $137M.
Buyers outnumbered sellers: 38 funds opened new TNGX positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $12.8M.
- 38 institutional investors held Tango Therapeutics (TNGX) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $137M of Tango Therapeutics stock for Q3 2020.
- 38 funds opened new Tango Therapeutics positions in Q3 2020 and 0 closed out, a net change of +38 holders.
- The largest Tango Therapeutics buyer in Q3 2020 was RA Capital Management, an estimated $12.8M added.
Based on aggregated 13F filings for Q3 2020.